Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trontinemab in Early Symptomatic Alzheimer's Disease
NCT07169578Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Sep 2025
- Primary completion
- Feb 2028
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Trontinemab with Placebo (2 arms). Primary endpoint: Clinical Dementia Rating, Sum of Boxes at 72 weeks. Started Sep 2025; status: active, not recruiting.
02
Drugs
trontinemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07169578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07169578.